Reports on Doxorubicin Therapy Findings from Chinese Academy of Sciences Provide New Insights (A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating from Beijing, People's Republic of China, by NewsRx correspondents, research stated, "Herein, we develop a co-delivery system of paclitaxel (PTX) and doxorubicin hydrochloride (DOX center dot HCl) based on methoxypoly(ethylene glycol)-block-poly(L-glutamic acid) (mPEG-b-PLG) for cancer treatment. PTX was grafted to the mPEG-b-PLG by esterification to give mPEG-b-PLG-g-PTX."
Our news editors obtained a quote from the research from the Chinese Academy of Sciences, "DOX center dot HCl was encapsulated via electrostatic interaction and hydrophobic stack between the DOX center dot HCl and mPEG-bPLG-g-PTX in aqueous solution. The release rate of DOX center dot HCl from the drug-loaded nanoparticles (mPEG-b-PLG-g-PTX-DOX) was slow at blood pH (pH 7.4), but obviously increased at endosome pH (pH 5.4). The mPEG-b-PLG-g-PTX-DOX exhibited slight synergistic effect in inhibition of proliferation of A549 and MCF-7 human cancer cells. For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-bPLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX center dot HCl and mPEG-b-PLG-g-PTX."
According to the news editors, the research concluded: "These results indicated that the mPEG-b-PLG-g-PTX-DOX would have great potential in cancer therapy."
For more information on this research see: A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation. International Journal of Pharmaceutics, 2014;471(1-2):412-420. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news editors report that additional information may be obtained by contacting Q. Li, Univ Chinese Academy Sci, Beijing 100049, People's Republic of China. Additional authors for this research include S.X. Lv, Z.H. Tang, M.H. Liu, D.W. Zhang, Y. Yang and X.S. Chen (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Pharmaceuticals, Cancer, Beijing, Taxoids, Oncology, Terpenes, Paclitaxel, Hydrocarbons, Nanoparticle, Cycloparaffins, Nanotechnology, Organic Chemicals, Mitotic Inhibitors, Drugs and Therapies, Emerging Technologies, Doxorubicin Hydrochloride, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC